

Fumaric Acids for the Treatment of Multiple Sclerosis

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

dimethyl fumarate (Tecfidera®)

Based on review of available data, the Company may consider brand dimethyl fumarate (Tecfidera®)[†] for the treatment of relapsing forms of multiple sclerosis to be **eligible for coverage**.^{**}

Patient Selection Criteria

Coverage eligibility for brand dimethyl fumarate (Tecfidera) will be considered when the following criteria are met:

- Patient has a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease; AND
- Patient has tried and failed (e.g. intolerance or inadequate response) GENERIC dimethyl fumarate unless there is clinical evidence or patient history that suggests the use of GENERIC dimethyl fumarate will be ineffective or cause an adverse reaction to the patient.
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary^{**} if not met.)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of brand dimethyl fumarate (Tecfidera) when the patient has not tried and failed the GENERIC dimethyl fumarate to be **not medically necessary**.^{**}

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of brand dimethyl fumarate (Tecfidera) for indications other than relapsing forms of multiple sclerosis to be **investigational**.^{*}

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

diroximel fumarate (Vumerity[®]), monomethyl fumarate (Bafiertam[™])

Based on review of available data, the Company may consider diroximel fumarate (Vumerity[®])[‡] or monomethyl fumarate (Bafiertam[™])[‡] for the treatment of relapsing forms of multiple sclerosis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for diroximel fumarate (Vumerity) or monomethyl fumarate (Bafiertam) will be considered when the following criterion is met:

- Patient has a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of diroximel fumarate (Vumerity) or monomethyl fumarate (Bafiertam) for indications other than relapsing forms of multiple sclerosis to be **investigational.***

Background/Overview

There are now three products that act as monomethyl fumarate to treat relapsing forms of multiple sclerosis. Tecfidera is dimethyl fumarate which is converted to monomethyl fumarate in the body, Vumerity is diroximel fumarate which is also converted to monomethyl fumarate, and Bafiertam is the active agent, monomethyl fumarate. Of these products, Tecfidera is currently the only one available in generic form. When dimethyl fumarate (Tecfidera, generics) is converted to monomethyl fumarate, methanol is also formed as a minor metabolite. This methanol formation may be related to the tolerability issues with the drug, such as gastrointestinal issues and flushing. In comparison, diroximel fumarate (Vumerity) generates much less methanol when it is converted to monomethyl fumarate and this may result in fewer adverse events. However, the prescribing information for Vumerity notes that the adverse event profile of Vumerity is consistent with the experience in the placebo-controlled clinical trials with Tecfidera. It should also be noted that the GI events and flushing with Tecfidera tended to decrease over time in clinical trials.

All of these products are orally administered and initiated at half of the recommended dose. After 7 days the dose is increased to a target of 190 mg twice a day for Bafiertam, 462 mg twice a day for Vumerity, and 240 mg twice a day for Tecfidera.

Fumaric Acids for the Treatment of Multiple Sclerosis

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

Multiple sclerosis is believed to have an immunologic mechanism that is characterized by demyelination in the brain and spinal cord. This is often expressed by symptoms such as visual and oculomotor abnormalities, weakness, urinary dysfunction, and mild cognitive impairment. In the most common forms of MS, patients experience remissions and exacerbations. Treatment includes corticosteroids for acute exacerbations and immunomodulatory (disease modifying) drugs to prevent exacerbations. Disease modifying drugs include oral products such as fingolimod (Gilenya), dimethyl fumarate (Tecfidera, generics), diroximel fumarate (Vumerity), teriflunomide (Aubagio), cladribine (Mavenclad[®])[‡], siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvory); subcutaneous and intramuscular injectable products such as glatiramer acetate (Copaxone[®], generics)[‡], ofatumumab (Kesimpta[®])[‡], interferon beta-1a (Avonex[®], Rebif[®])[‡], interferon beta-1b (Extavia[®], Betaseron[®])[‡], and peginterferon beta-1a (Plegridy[®])[‡]; and intravenous infusions such as ocrelizumab (Ocrevus[®])[‡], natalizumab (Tysabri[®])[‡], and alemtuzumab (Lemtrada[®])[‡].

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Tecfidera was approved in March 2013 for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Vumerity was approved in October 2019 for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Bafiertam was approved in April 2020 for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The efficacy and safety of Tecfidera were demonstrated in two studies that evaluated Tecfidera taken either twice or three times a day in patients with relapsing-remitting MS. The starting dose of Tecfidera was 120 mg two or three times a day for the first 7 days, followed by an increase to 240 mg two or three times a day. Both studies included patients who had experienced at least one relapse over the year preceding the trial or had a brain Magnetic Resonance Imaging (MRI) scan demonstrating at least one gadolinium-enhancing (Gd+) lesion within 6 weeks of randomization. The Expanded Disability Status Scale (EDSS) was also assessed and patients could have scores ranging from 0 to 5. Neurological evaluations were performed at baseline, month 6, and year 1 and 2 in a subset of patients.

Fumaric Acids for the Treatment of Multiple Sclerosis

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

Study 1 was a 2-year, randomized, double-blind, placebo-controlled study in 1234 patients with RRMS. The primary endpoint was the proportion of patients relapsed at 2 years. Patients were randomized to receive Tecfidera 240 mg twice a day (n=410), Tecfidera 240 mg three times a day (n=416), or placebo (n=408) for up to two years. Tecfidera had a statistically significant effect on the primary endpoint with 27% relapsing in the 240 mg twice daily group vs 46% in the placebo group ($p<0.0001$). The three times daily dose showed no additional benefit over the twice daily dose.

Study 2 was a 2-year, multicenter, randomized, double-blind, placebo-controlled study that also included an open-label comparator arm in patients with RRMS. The primary endpoint was the annualized relapse rate at two years. Patients were randomized to receive Tecfidera 240 mg twice a day (n=359), Tecfidera 240 mg three times a day (n=345), an open-label comparator (n=350), or placebo (n=363) for up to two years. Tecfidera had a statistically significant effect on the primary endpoint with an annualized relapse rate of 0.224 in the Tecfidera 240 mg twice daily arm compared to 0.401 in the placebo arm ($p<0.0001$). The Tecfidera 240 mg three times daily dose resulted in no additional benefit over the Tecfidera 240 mg twice daily dose.

Vumerity was approved based on bioavailability studies comparing oral dimethyl fumarate delayed-release capsules (Tecfidera) to Vumerity delayed-release capsules. These studies established the bioequivalence of Vumerity to Tecfidera in healthy subjects and in patients with relapsing forms of multiple sclerosis. Bafiertam was also approved based on bioavailability studies comparing it to dimethyl fumarate.

References

1. Vumerity [package insert]. Biogen, Inc. Cambridge, MA. Updated March 2020.
2. Vumerity Drug Evaluation. Express Scripts. Updated November 2019.
3. Bafiertam [package insert]. Banner Life Sciences LLC. High Point, NC. Updated April 2020.
4. Tecfidera [package insert]. Biogen, Inc. Cambridge, MA. Updated January 2021.

Policy History

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

09/03/2020 Medical Policy Committee review

09/09/2020 Medical Policy Implementation Committee approval. New policy.

03/04/2021 Medical Policy Committee review

03/10/2021 Medical Policy Implementation Committee approval. Title changed from “diroximel fumarate (Vumerity®)” to “diroximel fumarate (Vumerity®) and monomethyl fumarate (Bafiertam™)”. Added new drug, Bafiertam, to policy with relevant background information.

10/07/2021 Medical Policy Committee review

10/13/2021 Medical Policy Implementation Committee approval. Title changed from “diroximel fumarate (Vumerity®) and monomethyl fumarate (Bafiertam™)” to “Fumaric Acids for the Treatment of Multiple Sclerosis”. Added Tecfidera to the policy with relevant criteria. Removed age requirement and step from Vumerity criteria.

Fumaric Acids for the Treatment of Multiple Sclerosis

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Updated criteria for Bafiertam to match Vumerity.
08/03/2023	Medical Policy Committee review
08/09/2023	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/01/2024	Medical Policy Committee review
08/14/2024	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/07/2025	Medical Policy Committee review
08/13/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/12/2026	Pre Pharmacy & Therapeutics Committee review.
08/19/2026	Pharmacy & Therapeutics Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 08/2027

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

Fumaric Acids for the Treatment of Multiple Sclerosis

Policy # 00719

Original Effective Date: 10/12/2020

Current Effective Date: 09/01/2026

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.